Search Results

Filter
  • 1-10 of  2,092 results for ""Biological Availability""
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Intercalation of the anticancer drug lenalidomide into montmorillonite for bioavailability improvement: a computational study.

  • Authors : Meruvia-Rojas YV; Andalusian Earth Sciences Institute, CSIC, Av. de Las Palmeras, 4, 18100, Armilla, Granada, Spain.; Faculty of Pharmacy, University of Granada, Granada, Spain.

Subjects: Bentonite*/Bentonite*/Bentonite*/chemistry ; Lenalidomide*/Lenalidomide*/Lenalidomide*/chemistry ; Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/chemistry

  • Source: Journal of molecular modeling [J Mol Model] 2024 Dec 04; Vol. 31 (1), pp. 5. Date of Electronic Publication: 2024 Dec 04.Publisher: Springer Country of Publication: Germany NLM ID: 9806569 Publication Model: Electronic Cited Medium: Internet ISSN: 0948-5023

Record details

×
Academic Journal

Discovery of ZLC491 as a Potent, Selective, and Orally Bioavailable CDK12/13 PROTAC Degrader.

  • Authors : Zhou L; International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, College of Pharmacy, Jinan University, 855 Xingye Avenue East, Guangzhou 511400, China.; State Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, #345 Lingling Rd., Shanghai 200032, China.

Subjects: Cyclin-Dependent Kinases*/Cyclin-Dependent Kinases*/Cyclin-Dependent Kinases*/antagonists & inhibitors ; Cyclin-Dependent Kinases*/Cyclin-Dependent Kinases*/Cyclin-Dependent Kinases*/metabolism ; Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/pharmacology

  • Source: Journal of medicinal chemistry [J Med Chem] 2024 Oct 24; Vol. 67 (20), pp. 18247-18264. Date of Electronic Publication: 2024 Oct 10.Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet

Record details

×
Academic Journal

Selective and Orally Bioavailable c-Met PROTACs for the Treatment of c-Met-Addicted Cancer.

  • Authors : Ying S; The Key Laboratory of Zhejiang Province for Aptamers and Theranostics, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China.; Chi H

Subjects: Proto-Oncogene Proteins c-met*/Proto-Oncogene Proteins c-met*/Proto-Oncogene Proteins c-met*/metabolism ; Proto-Oncogene Proteins c-met*/Proto-Oncogene Proteins c-met*/Proto-Oncogene Proteins c-met*/antagonists & inhibitors ; Proteolysis*/Proteolysis*/Proteolysis*/drug effects

  • Source: Journal of medicinal chemistry [J Med Chem] 2024 Oct 10; Vol. 67 (19), pp. 17053-17069. Date of Electronic Publication: 2024 Sep 30.Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet

Record details

×
Academic Journal

Discovery of Novel Heterotricyclic Compounds as DNA-Dependent Protein Kinase (DNA-PK) Inhibitors with Enhanced Chemosensitivity, Oral Bioavailability, and the Ability to Potentiate Cancer Immunotherapy.

  • Authors : Cheng B; Key Laboratory of Joint Diagnosis and Treatment of Chronic Liver Disease and Liver Cancer of Lishui, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui People's Hospital, Lishui, Zhejiang 323000, China.; Hubei Key Laboratory of Renal Disease Occurrence and Intervention, Department of Pharmacy, School of Medicine, Hubei Polytechnic University, Huangshi, Hubei 435003, P. R. China.

Subjects: DNA-Activated Protein Kinase*/DNA-Activated Protein Kinase*/DNA-Activated Protein Kinase*/antagonists & inhibitors ; DNA-Activated Protein Kinase*/DNA-Activated Protein Kinase*/DNA-Activated Protein Kinase*/metabolism ; Biological Availability*

  • Source: Journal of medicinal chemistry [J Med Chem] 2024 Apr 25; Vol. 67 (8), pp. 6253-6267. Date of Electronic Publication: 2024 Apr 08.Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet

Record details

×
Academic Journal

Nanoparticulation improves bioavailability of Erlotinib.

  • Authors : Yang KM; a Department of Biochemistry and Molecular Biology , Yonsei University College of Medicine , Seoul , Korea.; Shin IC

Subjects: Biological Availability*; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*pharmacokinetics ; Erlotinib Hydrochloride/Erlotinib Hydrochloride/Erlotinib Hydrochloride/*pharmacokinetics

  • Source: Drug development and industrial pharmacy [Drug Dev Ind Pharm] 2017 Sep; Vol. 43 (9), pp. 1557-1565. Date of Electronic Publication: 2017 May 30.Publisher: Informa Healthcare Country of Publication: England NLM ID: 7802620 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Bioavailability studies and anticancer properties of malvidin based anthocyanins, pyranoanthocyanins and non-oxonium derivatives.

  • Authors : Oliveira H; School of Food Science and Engineering, Wuhan Polytechnic University, 430023, Wuhan, China.; Wu N

Subjects: Biological Availability*; Anthocyanins/Anthocyanins/Anthocyanins/*pharmacology ; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*pharmacology

  • Source: Food & function [Food Funct] 2016 May 18; Vol. 7 (5), pp. 2462-8. Date of Electronic Publication: 2016 May 11.Publisher: Royal Society of Chemistry Country of Publication: England NLM ID: 101549033 Publication Model: Print-Electronic Cited Medium: Internet

Record details

×
Academic Journal

Pharmacology of aging and cancer: how useful are pharmacokinetic tests?.

  • Authors : Lichtman SM; Memorial Sloan-Kettering Cancer Center, Commack, NY 11725, USA.

Subjects: Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/classification ; Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/pharmacokinetics ; Biological Availability*

  • Source: Interdisciplinary topics in gerontology [Interdiscip Top Gerontol] 2013; Vol. 38, pp. 104-23. Date of Electronic Publication: 2013 Jan 17.Publisher: Karger Country of Publication: Switzerland NLM ID: 0135125 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1662-3800

Record details

×
Academic Journal

Metabolism, oral bioavailability and pharmacokinetics of chemopreventive kaempferol in rats.

  • Authors : Barve A; Graduate Program in Pharmaceutical Science, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA.; Chen C

Subjects: Biological Availability* ; Dose-Response Relationship, Drug*; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*pharmacokinetics

  • Source: Biopharmaceutics & drug disposition [Biopharm Drug Dispos] 2009 Oct; Vol. 30 (7), pp. 356-65.Publisher: Wiley Country of Publication: England NLM ID: 7911226 Publication Model: Print Cited Medium: Internet ISSN: 1099-081X (Electronic)

Record details

×
Academic Journal

[Clinical problems of optimum bioavailability, in particular in cytostatic therapy (author's transl)].

Subjects: Biological Availability* ; Biopharmaceutics*; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*metabolism

  • Source: Arzneimittel-Forschung [Arzneimittelforschung] 1976; Vol. 26 (1A), pp. 130-5.Publisher: Editio Cantor Country of Publication: Germany NLM ID: 0372660 Publication Model: Print Cited Medium: Print ISSN: 0004-4172 (Print)

Record details

×
  • 1-10 of  2,092 results for ""Biological Availability""